Galectin director sells 30,000 shares at ~$5

Galectin Therapeutics director Harold H. Shlevin reported option exercises paired with share sales in Galectin Therapeutics Inc. common stock.

Rhea-AI Filing Summary

Galectin Therapeutics director Harold H. Shlevin reported option exercises paired with share sales in Galectin Therapeutics Inc. common stock. On June 26 and June 29, 2026, he exercised stock options to acquire a total of 30,000 shares at an exercise price of $1.23 per share and sold 30,000 shares in open-market transactions.

Sales on June 26 covered 7,732 shares at $5.00 per share, while June 29 sales covered 22,268 shares at a weighted average price of $5.04, with individual trades ranging from $5.00 to $5.12. The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on August 29, 2025. After these trades, Shlevin directly holds 6,500 shares of Galectin common stock, and the exercised options had fully vested on December 31, 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 30,000 shares ($114K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Shlevin Harold H.

Role Director

Sold 30,000 shs ($151K)

Approx. gross sale proceeds $151K

Approx. exercise cost $37K

Approx. pre-tax spread $114K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	22,268	$0.00	$0.00
Exercise	Common Stock	22,268	$1.23	$27K
Sale	Common Stock	22,268	$5.04	$112K
Exercise	Stock Option (right to buy)	7,732	$0.00	$0.00
Exercise	Common Stock	7,732	$1.23	$10K
Sale	Common Stock	7,732	$5.00	$39K

Holdings After Transaction: Stock Option (right to buy) — 30,000 contracts (Direct); Common Stock — 6,500 shares (Direct)

Footnotes (4)

1. F1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025
2. F2. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. F3. The options vested 100% on December 31, 2025.
4. F4. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Key Figures

Total shares sold: 30,000 shares June 26 sale: 7,732 shares at $5.00/share June 29 weighted average price: $5.04/share +5 more

8 metrics

Total shares sold 30,000 shares Open-market sales of common stock on June 26 and 29, 2026

June 26 sale 7,732 shares at $5.00/share Common stock sale on June 26, 2026

June 29 weighted average price $5.04/share 22,268-share sale; individual trades $5.00–$5.12 on June 29, 2026

Options exercised 30,000 shares Stock option exercises on June 26 and 29, 2026

Option exercise price $1.23/share Exercise or conversion price for stock options

Post-transaction holdings 6,500 shares Common stock held directly after June 29, 2026 transactions

Option vesting date December 31, 2025 Options vested 100% before exercise in 2026

10b5-1 plan adoption August 29, 2025 Date Shlevin adopted Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 plan, Stock Option (right to buy), weighted average sale price, open-market sale, +1 more

5 terms

Rule 10b5-1 plan regulatory

"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise or conversion price of 1.2300"

weighted average sale price financial

"This amount represents the weighted average sale price of such transactions."

open-market sale financial

"transaction_action: open-market sale; transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion; transaction_code_description: Exercise or conversion of derivative security"

FAQ

What insider transactions did Galectin Therapeutics (GALT) report for Harold H. Shlevin?

Harold H. Shlevin exercised stock options for 30,000 Galectin Therapeutics shares and sold 30,000 common shares in open-market transactions on June 26 and June 29, 2026. These trades combined option exercises with immediate share sales.

At what prices did Harold H. Shlevin sell GALT shares in his recent Form 4?

Shlevin sold 7,732 Galectin shares at $5.00 on June 26, 2026 and 22,268 shares at a weighted average price of $5.04 on June 29, 2026. Individual June 29 trades ranged between $5.00 and $5.12 per share.

What was the option exercise price in Harold H. Shlevin’s GALT Form 4 filing?

The exercised stock options carried an exercise price of $1.23 per share. Shlevin used these options to acquire a total of 30,000 Galectin common shares before selling the same number of shares in the market shortly afterward.

How many GALT shares does Harold H. Shlevin hold after the reported transactions?

Following the June 26 and June 29, 2026 transactions, Shlevin directly holds 6,500 shares of Galectin Therapeutics common stock. This figure reflects his remaining position after exercising options and selling 30,000 shares in open-market trades.

Were Harold H. Shlevin’s recent GALT share sales under a Rule 10b5-1 plan?

Yes. The filing states the reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2025. Such pre-arranged plans automate trades and can reduce the significance of trade timing as a market signal.

When did the options exercised by Harold H. Shlevin in GALT fully vest?

The stock options exercised by Shlevin in these transactions vested 100% on December 31, 2025. He then exercised those options on June 26 and June 29, 2026 to acquire 30,000 shares before selling an equivalent number of common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 07:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shlevin Harold H.

(Last) (First) (Middle)

C/O GALECTIN THERAPEUTICS INC.

4960 PEACHTREE INDUSTRIAL BLVD., STE 240

(Street)

NORCROSS GEORGIA 30071

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2026		M(1)		7,732	A	$1.23	14,232	D
Common Stock	06/26/2026		S(1)		7,732	D	$5(2)	6,500	D
Common Stock	06/29/2026		M(1)		22,268	A	$1.23	28,768	D
Common Stock	06/29/2026		S(1)		22,268	D	$5.04(4)	6,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.23	06/26/2026		M(1)			7,732	12/31/2025(3)	01/23/2035	Common Stock	7,732	$0	52,268	D
Stock Option (right to buy)	$1.23	06/29/2026		M(1)			22,268	12/31/2025(3)	01/23/2035	Common Stock	22,268	$0	30,000	D

Explanation of Responses:

1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025

2. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. The options vested 100% on December 31, 2025.

4. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

	Jack W. Callicutt, by power of attorney	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)